The VEGF signaling pathway in cancer: The road ahead

Chinese Journal of Cancer

Volumn 32, Issue 6, 2013, Pages 297-302

  Stacker, Steven A ^a   Achen, Marc G ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Cancer metastasis; Monoclonal antibody; Vascular endothelial growth factor (VEGF); VEGF receptors

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; PLACENTAL GROWTH FACTOR; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ARTICLE; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; LYMPHANGIOGENESIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84878924069     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10319     Document Type: Article

References (69)

1. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VE GF antibody for treating cancer. Nat Rev Drug Discov, 2004,3:391-400.
2. Ferrara N., VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2002,2:795-803.
3. Lewis WH. The vascular pattern of tumors. Johns Hopkins Hosp Bull, 1927,41:156-162.
4. Algire GH, Chalkley HW. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst, 1945,6:73-85.
5. Folkman J, Long DM, Becker FF. Growth and metastasis of tumor in organ culture. Cancer, 1963,16:453-467.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971,285:1182-1186.
7. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-in duced angiogenesis suppresses tumour growth in vivo. Nature, 1993,362:841-844.
8. Senger DR, Galli SJ, Dvorak AM, et al. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascities fluid. Science, 1983,219:983-985.
9. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 1989,246:1309-1312.
10. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989,246:1306-1309.
11. McDonald NQ, Hendrickson WA. A structural superfamily of growth factors containing a cystine knot motif. Cell, 1993,73: 421-424.
12. Olofsson B, Pajusola K, von Euler G, et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem, 1996,271:19310-19317.
13. Paavonen K, Horelli-Kuitunen N, Chilov D, et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation, 1996,93:1079-1082.
14. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996,15:290-298.
15. Yamada Y, Nezu JI, Shimane M, et al. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics, 1997,42:483-488.
16. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA, 1998,95:548-553.
17. Orlandini M, Marconcini L, Ferruzzi R, et al. Identification of a c-fos-in duced gene that is related to the platelet-de rived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA, 1996,93:11675-11680.
18. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA, 1991,88: 9267-9271.
19. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J, 2011,437:169-183.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004,350:2335-2342.
21. Halford MM, Tebbutt NC, Desai J, et al. Towards the biomarker-gu ided rational use of anti-an giogenic agents in the treatment of metastatic colorectal cancer. Colorectal Cancer, 2012,1:149-161.
22. Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: a meta-an alysis of first-lin e phase III studies and a critical reappraisal of available evidence. J Oncol, 2012,2012:417-673.
23. Fischer C, Mazzone M, Jonckx B, et al. Flt1 and its ligands VEGFB and PLGF: drug targets for anti-an giogenic therapy? Nat Rev Cancer, 2008,8:942-956.
24. Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PL GF antibodies efficacy. Proc Natl Acad Sci U S A, 2011,108: 11590-11595.
25. Bais C, Wu X, Yao J, et al. PLGF blockade does not inhibit angiogenesis during primary tumor growth. Cell, 2010,141: 166-177.
26. Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and eye disease. Cell, 2010,141:178-190.
27. Fischer C, Jonckx B, Mazzone M, et al. Anti-PL GF inhibits growth of VEGF(R)-in hibitor-resistant tumors without affecting healthy vessels. Cell, 2007,131:463-475.
28. Ribatti D. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treat Rev, 2011,37:344-352.
29. Kanda M, Nomoto S, Nishikawa Y, et al. Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pa thological parameters. J Surg Oncol, 2008,98:190-196.
30. Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-sp ecific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mecha-nisms. Circulation, 2009,119:845-856.
31. Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature, 2010,464:917-921.
32. Scotney PD, MacKenzie A, Maccarone P, et al. Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies. Clin Exp Pharmacol Physiol, 2002,29:1024-1029.
33. Albrecht I, Kopfstein L, Strittmatter K, et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One, 2010,5:e14109.
34. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996,15:290-298.
35. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J, 1997,16:3898-3911.
36. Stacker SA, Stenvers K, Caesar C, et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-co valent homodimers. J Biol Chem, 1999,274:32127-32136.
37. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymph-angiogenesis in transgenic mice. EMBO J, 2001,20:1223-1231.
38. Tammela T, Zarkada G, Nurmi H, et al. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing notch signalling. Nature Cell Biol, 2011,13:1202-1213.
39. Stacker SA, Williams RA, Achen MG. Lymphangiogenic growth factors as markers of tumor metastasis. APMIS, 2004,112:539-549.
40. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med, 2001,7:192-198.
41. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J, 2001,20:672-682.
42. Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy. J Exp Med, 2001,194:F37-F42.
43. McColl BK, Baldwin ME, Roufail S, et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med, 2003,198:863-868.
44. McColl BK, Paavonen K, Karnezis T, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J, 2007,21: 1088-1098.
45. Debinski W, Slagle-Webb B, Achen MG, et al. VEGF-D is an X-lin ked/AP-1 regulated putative onco-an giogen in human glioblastoma multiforme. Mol Med, 2001,7:598-608.
46. Achen MG, Williams RA, Minekus MP, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol, 2001,193: 147-154.
47. White JD, Hewett PW, Kosuge D, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res, 2002,62:1669-1675.
48. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Prognostic significance of vascular endothelial growth factor-D in breast carcinoma with long-te rm follow-up. Clin Cancer Res, 2003,9: 716-721.
49. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Med, 2001,7:186-191.
50. Kopfstein L, Veikkola T, Djonov VG, et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol, 2007,170:1348-1361.
51. Karnezis T, Shayan R, Caesar C, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell, 2012,21:181-195.
52. Achen MG, McColl BK, Stacker SA. Focus on lymphangio-genesis in tumor metastasis. Cancer Cell, 2005,7:121-127.
53. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann NY Acad Sci, 2008,1131:225-234.
54. Harris NC, Paavonen K, Davydova N, et al. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J, 2011,25:2615-2625.
55. Achen MG, Roufail S, Domagala T, et al. Monoclonal antibodies to vascular endothelial growth factor-D block interactions with both VEGF receptor-2 and VEGF receptor-3. Eur J Biochem, 2000,267:2505-2515.
56. Davydova N, Roufail S, Streltsov VA, et al. The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding. J Mol Biol, 2011,407:581-593.
57. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res, 2007,13:5544s-5548s.
58. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst, 2005,97: 14-21.
59. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst, 2002,94:819-825.
60. Achen MG, Mann GB, Stacker SA. Targeting lymphangio-genesis to prevent tumour metastasis. Br J Cancer, 2006,94: 1355-1360.
61. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-te rm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 2009,15:232-239.
62. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 2009,15: 220-231.
63. Singh M, Couto SS, Forrest WF, et al. Anti-VE GF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol, 2012,227:417-430.
64. Chung AS, Kowanetz M, Wu X, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol, 2012,227:404-416.
65. Yakes FM, Chen J, Tan J, et al. Cabozantinib (xl184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011,10:2298-2308.
66. You WK, Sennino B, Williamson CW, et al. VEGF and c-M et blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011,71:4758-4768.
67. Qin L, Bromberg-White JL, Qian CN. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed. Adv Cancer Res, 2012,113:191-239.
68. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet, 2012,379:1591-1601.
69. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-te rm risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 2011,377:31-41.